Shares of Doximity, Inc. (NASDAQ:DOCS – Get Rating) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $50.00.
Several equities analysts have recently weighed in on DOCS shares. Raymond James reduced their target price on shares of Doximity from $60.00 to $40.00 in a research note on Wednesday, May 18th. Guggenheim reduced their target price on shares of Doximity from $70.00 to $52.00 and set a “buy” rating for the company in a research note on Wednesday, May 18th. Morgan Stanley cut their price objective on shares of Doximity from $55.00 to $35.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 18th. Bank of America cut their price objective on shares of Doximity from $55.00 to $36.00 and set a “neutral” rating for the company in a research report on Wednesday, May 18th. Finally, Robert W. Baird cut their price objective on shares of Doximity from $68.00 to $45.00 in a research report on Wednesday, May 18th.
NASDAQ DOCS opened at $36.03 on Thursday. Doximity has a 52-week low of $27.06 and a 52-week high of $107.79. The company has a 50-day simple moving average of $37.40 and a 200 day simple moving average of $46.29. The company has a market capitalization of $6.96 billion and a PE ratio of 52.22.
In other Doximity news, Director Kira Scherer Wampler sold 2,200 shares of Doximity stock in a transaction that occurred on Friday, April 1st. The shares were sold at an average price of $53.10, for a total transaction of $116,820.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CRO Paul W. Jorgensen bought 15,000 shares of the company’s stock in a transaction on Friday, May 20th. The shares were bought at an average price of $32.19 per share, with a total value of $482,850.00. Following the completion of the transaction, the executive now owns 197,676 shares of the company’s stock, valued at $6,363,190.44. The disclosure for this purchase can be found here. Insiders own 45.21% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Central Bank & Trust Co. lifted its holdings in shares of Doximity by 400.0% in the 1st quarter. Central Bank & Trust Co. now owns 500 shares of the company’s stock worth $26,000 after acquiring an additional 400 shares during the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of Doximity in the 3rd quarter worth approximately $27,000. Washington Trust Advisors Inc. bought a new stake in shares of Doximity in the 1st quarter worth approximately $28,000. Signaturefd LLC lifted its holdings in shares of Doximity by 460.0% in the 1st quarter. Signaturefd LLC now owns 728 shares of the company’s stock worth $38,000 after acquiring an additional 598 shares during the last quarter. Finally, New York State Common Retirement Fund bought a new stake in shares of Doximity in the 1st quarter worth approximately $45,000. Hedge funds and other institutional investors own 67.88% of the company’s stock.
About Doximity (Get Rating)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
- Get a free copy of the StockNews.com research report on Doximity (DOCS)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.